Table 1.
Case | Diagnosis month/year | Age, years | Gender | Exposure | Risk factors | Infection site | Treatment | Outcome | Relapse |
---|---|---|---|---|---|---|---|---|---|
1 | 4/2021 | 60 | M | Floodwater | Diabetes, alcohol excess, smoker | Blood, lung, brain | MEM, 56 days; SXT, 6 months | Alive | No |
2 | 5/2021 | 5 | M | Mud | None | Skin | CAZ, 14 days; SXT, 6 months | Alive | No |
3 | 6/2021 | 51 | F | Mud | Diabetes, smoker | Lung, bone (hallux), abscess (liver) | CAZ, 28 days; SXT, 6 months | Alive | No |
4 | 2/2022 | 77 | F | Floodwater | Pancreatic cancer (chemotherapy) | Blood | MEM, 18 days; AMC, 4 months | Dead | – |
5 | 2/2022 | 71 | M | Mud | Alcohol excess, ex-smoker, prostate cancer (radiotherapy) | Blood, lung, bone (femur), brain (possible) | MEM, 56 days; SXT, 4 months | Alive | No |
6 | 3/2022 | 83 | M | Unknown | Chronic kidney disease, lung disease, chronic liver disease, immunosuppression (azathioprine) | Blood, lung | MEM, 28 days; SXT, 3 months | Alive | No |
7 | 3/2022 | 59 | M | Floodwater | Lung disease, smoker | Blood | MEM, 14 days; SXT, 3 months | Alive | No |
8 | 3/2022 | 63 | M | Floodwater | Diabetes, smoker | Blood, joint (shoulder) | MEM, 28 days; SXT, 6 months | Alive | No |
9 | 3/2022 | 66 | M | Floodwater | Smoker | Blood, lung, abscess (spleen), bone (humerus), skin | MEM, 28 days; SXT, 1 month; AMC, 6 months | Alive | No |
10 | 3/2022 | 71 | M | Floodwater | Alcohol excess | Blood, lung | AMC, 1 day | Dead | – |
11 | 4/2022 | 11 | M | Unknown | None | Skin, bone (tibia) | MEM, 47 days; CAZ, 56 days; SXT, 8 months | Alive | No |
12* | 4/2022 | 74 | M | Unknown | Diabetes, alcohol excess | Blood, lung, abscess (liver, spleen, prostate), skin | MEM, 77 days; SXT, 6 months | Alive | No |
13 | 5/2022 | 60 | M | Floodwater | Diabetes, alcohol excess, smoker | Blood, abscess (prostate) | CAZ, 14 days; MEM, 14 days | Alive | No |
14 | 6/2022 | 82 | M | Floodwater | Diabetes | Skin | MEM, 14 days; SXT, 3 months | Alive | No |
AMC = amoxicillin–clavulanic acid; CAZ = ceftazidime; F = female; M = male; MEM = meropenem; SXT = trimethoprim–sulfamethoxazole.
Presented with chronic melioidosis (symptoms > 2 months).